National Bank of Canada FI raised its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 5,472.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 1,019,526 shares of the company's stock after acquiring an additional 1,001,230 shares during the period. National Bank of Canada FI owned approximately 0.09% of Teva Pharmaceutical Industries worth $22,470,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB bought a new stake in Teva Pharmaceutical Industries in the third quarter valued at about $50,000. Ameliora Wealth Management Ltd. bought a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at about $66,000. IFP Advisors Inc raised its position in shares of Teva Pharmaceutical Industries by 96.1% in the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after acquiring an additional 1,960 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in Teva Pharmaceutical Industries during the 4th quarter worth approximately $104,000. Finally, Assetmark Inc. grew its holdings in Teva Pharmaceutical Industries by 1,370.3% during the fourth quarter. Assetmark Inc. now owns 5,205 shares of the company's stock valued at $115,000 after purchasing an additional 4,851 shares during the period. Institutional investors and hedge funds own 54.05% of the company's stock.
Teva Pharmaceutical Industries Stock Up 0.7 %
Shares of Teva Pharmaceutical Industries stock traded up $0.09 during trading on Monday, reaching $13.89. The stock had a trading volume of 12,973,614 shares, compared to its average volume of 9,757,944. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The company has a market capitalization of $15.75 billion, a price-to-earnings ratio of -9.62, a P/E/G ratio of 1.44 and a beta of 0.72. The stock has a fifty day moving average price of $16.52 and a two-hundred day moving average price of $18.01. Teva Pharmaceutical Industries Limited has a 52 week low of $12.51 and a 52 week high of $22.80.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Sell-side analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research firms have weighed in on TEVA. Bank of America cut their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. UBS Group dropped their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday, January 30th. StockNews.com raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Friday. Piper Sandler raised their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, January 17th. Finally, Barclays cut their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Teva Pharmaceutical Industries has an average rating of "Moderate Buy" and an average price target of $23.43.
Read Our Latest Stock Report on TEVA
Teva Pharmaceutical Industries Company Profile
(
Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Further Reading
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
